The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...
The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in ... standalone therapy for treatment-resistant depression, which is when trying at least two standard ...